1. In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.
  2. The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who have recovered from COVID-19 is being implemented at hospitals in New Mexico as one potential treatment option.
  3. Based on available data, the MAT cannot recommend for or against CCP use.
  4. Randomized controlled trials have not yet shown a clinically significant benefit from CCP. However, matched-control studies suggest that a mortality benefit may be seen if high-titer CCP is transfused early in the patient’s clinical course (either within 72 hours of diagnosis or within 72 hours of admission).
  5. If CCP will be transfused, the MAT recommends only doing so if administered within 72 hours of the patient’s first COVID admission.
  6. The optimal dose of CCP (1 unit vs 2 units) is not yet known. Until the state and national supply of CCP increases, transfusion of 1 unit per patient is recommended so more patients have access to the therapy.
  7. Clinicians may order CCP from their hospital’s blood bank using locally established procedures.
  8. In order for the patient to receive CCP through the EUA, they must be consented for blood using their local hospital’s policies and procedures and be provided with the “FDA CCP Fact Sheet for Patients/Caregivers.”

Download this resource